CTLA4 and peripheral neuropathy: Applying the ROR, we found that the anti-CTLA-4 agent ipilimumab was associated with an increased reporting probability of neurologic irADRs belonging to “Peripheral neuropathies” (Figure 6A) and “Headaches” HLGTs (Figure 6B) when compared with all other ICI classes.